Related Experiment Video

Updated: Sep 21, 2025

Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)
07:15

Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)

Published on: July 3, 2025

258

Pharmacological developments in antihypertensive treatment through nitric oxide-cGMP modulation

Annika A Jüttner1, A H Jan Danser1, Anton J M Roks1

  • 1Department of Internal Medicine, Division of Vascular Disease and Pharmacology, Erasmus Medical Center, Erasmus University, Rotterdam, The Netherlands.

Advances in Pharmacology (San Diego, Calif.)
|June 6, 2022
PubMed

Insights

Optimizing hypertension treatment by targeting nitric oxide-cyclic guanosine monophosphate signaling shows promise. This pathway is key for vasodilation, offering a viable strategy to manage high blood pressure risks.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Molecular Biology

Background:

  • Current hypertension treatments targeting vasoconstriction, cardiac contractility, and blood volume regulation often fail to achieve target blood pressure in outpatients.
  • The nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway is a crucial mediator of vasodilation.

Purpose of the Study:

  • To review challenges within the NO-cGMP signaling system in hypertension.
  • To explore existing and ongoing attempts to correct these signaling problems for improved hypertension management.

Main Methods:

  • Review of existing literature on NO-cGMP signaling in hypertension.
  • Analysis of therapeutic strategies targeting the NO-cGMP pathway.
  • Discussion of potential applications of newly developed, clinically safe medications.

Main Results:

  • The NO-cGMP pathway presents a significant therapeutic target for hypertension.
  • Several strategies to address dysfunctions in this pathway are under investigation.
  • Existing medications approved for other conditions may be repurposed for essential systemic hypertension.

Conclusions:

  • Despite research challenges, stimulating the NO-cGMP pathway remains a promising strategy for hypertension treatment.
  • Targeting NO-cGMP signaling offers a viable approach to mitigate the health risks associated with chronic hypertension.

Keywords:
Blood pressureCardiovascularHypertensionMitochondrialNitric oxideOxidative stressPhosphodiesteraseProtein kinase GSoluble guanylyl cyclasecGMP

More Related Videos

Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds08:23

Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds

Published on: February 16, 2022

4.3K
Preparation of Rat Skeletal Muscle Homogenates for Nitrate and Nitrite Measurements07:19

Preparation of Rat Skeletal Muscle Homogenates for Nitrate and Nitrite Measurements

Published on: July 29, 2021

2.4K

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.2K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
663
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
772
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
256
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
527
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
712